BuzzFeed is at an earnings turning point with narrowing losses, stable revenue, and hidden asset potential. Find out why BZFD ...
Avacta is slated to present the final Phase Ia dose escalation data for our lead program, faridoxorubicin. This will be at ESMO 2025 in Berlin, a little bit later next month in October of 2025. There, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback